GSK Partners with CAMP4 Therapeutics in $440M+ RNA Deal for Neurodegenerative and Kidney Diseases
Key Insights
GSK has entered a strategic collaboration with CAMP4 Therapeutics (search), paying $17.5 million upfront to leverage the biotech's RAP Platform for developing antisense oligonucleotides targeting neurodegenerative and kidney diseases (search).
The partnership could reach over $440 million in total value through development and commercial milestones, plus tiered royalties on future product sales.
CAMP4's proprietary platform identifies regulatory RNAs (search) that control gene expression (search), with the goal of developing therapeutics that amplify target gene expression to restore healthy protein levels.
GSK has entered into a strategic research collaboration with CAMP4 Therapeutics (search) to develop novel antisense oligonucleotide (ASO) therapeutics for neurodegenerative and kidney diseases (search), marking another significant investment in RNA-targeting therapies by a major pharmaceutical company.
The partnership, announced Thursday, involves a $17.5 million upfront payment from GSK to access CAMP4's proprietary RAP Platform, which identifies regulatory RNAs (search) (regRNAs) that control the expression of multiple gene targets. CAMP4 stands to receive up to $440 million in additional development and commercial milestone payments, along with tiered royalties on future product sales.
Platform Technology and Therapeutic Approach
CAMP4's RAP Platform enables the mapping of regulatory RNAs (search) and generation of therapeutic candidates designed to amplify mRNA by targeting regRNAs, which act as master regulators of gene expression (search). The approach aims to develop disease-modifying treatments for genetic diseases where amplifying healthy protein levels may offer therapeutic benefits.
"Protein under-expression plays a critical role in diseases such as neurodegenerative and kidney disease," said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4. "Our collaboration with GSK, focused on the rapid identification of novel targets and potential ASO therapeutics that increase the expression of validated genetic targets, underscores the potential of our discovery platform to create transformational medicines for patients."
The collaboration targets haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, where a modest increase in protein expression may have the potential to be clinically meaningful.
Division of Responsibilities
Under the agreement terms, CAMP4 will utilize its RAP Platform to identify regRNAs controlling the expression of multiple gene targets and generate regRNA-targeting ASO candidates that amplify target gene expression (search). GSK will assume responsibility for further development and commercialization of ASO drug candidates identified through the collaboration.
Chris Austin, SVP Research Technologies at GSK, commented: "We are excited to collaborate with CAMP4, combining their RNA discovery platform to increase specific gene activity with GSK's expertise in therapeutic oligonucleotides, genetics and advanced laboratory and data technologies. This agreement aims to drive the development of novel medicines for neurodegenerative and kidney disease and demonstrates our approach of harnessing cutting-edge technologies to deliver transformational therapies for patients."
Industry Context and Competitive Landscape
The CAMP4 partnership positions GSK within the competitive RNA therapeutics space alongside other major pharmaceutical companies making significant investments. The deal joins GSK's Big Pharma peers in a year-end dealmaking rush, following Bristol Myers Squibb (search)'s recent $1 billion partnership with China's Harbour BioMed (search) for multi-specific antibodies and Roche's $1.1 billion collaboration with Caris Life Sciences (search) for AI-driven drug development.
The collaboration also places GSK in direct competition with Novartis, which acquired Avidity Biosciences (search) for $12 billion in October. Like CAMP4, Avidity develops RNA-targeting therapies, though using a different approach with antibody-oligonucleotide conjugates consisting of monoclonal antibodies that target specific tissues and nucleotide payloads that deliver therapeutic effects. Avidity focuses on neuromuscular disorders, including Duchenne muscular dystrophy (search) and myotonic dystrophy type 1 (search).
While the companies have not disclosed the specific number of programs under the alliance, a representative confirmed there will be "multiple candidates" developed through the collaboration, suggesting a broad-based approach to targeting various neurodegenerative and kidney disease indications.